Overview

ALPN-202 With PD-1 Inhibition in Advanced Malignancies

Status:
Recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
This is a cohort-based, open-label dose escalation and expansion study in adults with advanced solid tumors or lymphoma.
Phase:
Phase 1
Details
Lead Sponsor:
Alpine Immune Sciences, Inc.
Treatments:
Pembrolizumab